As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/28/20  HCA Healthcare, Inc.              8-K:2,7,8,9 1/28/20   11:402K                                   Donnelley … Solutions/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     28K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    152K 
 9: R1          Document and Entity Information                     HTML     47K 
 7: XML         IDEA XML File -- Filing Summary                      XML     11K 
11: XML         XBRL Instance -- d879257d8k_htm                      XML     13K 
 6: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- hca-20200128_lab                      XML     53K 
 5: EX-101.PRE  XBRL Presentations -- hca-20200128_pre               XML     34K 
 3: EX-101.SCH  XBRL Schema -- hca-20200128                          XSD     12K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
 8: ZIP         XBRL Zipped Folder -- 0001193125-20-016154-xbrl      Zip     24K 

 i false  i 0000860730 0000860730 2020-01-28 2020-01-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM  i 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  i January 28, 2020

 i HCA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

i Delaware		i 001-11239		i 27-3865930
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
i One Park Plaza,  i Nashville,  i Tennessee				i 37203
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code:  i (615)  i 344-9551

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common Stock, $.01 par value per share		i HCA		i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company      i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Item 2.02. Results of Operations and Financial Condition.

On January 28, 2020, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2019, the text of which is set forth as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

On January 28, 2020, the Company issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2019, the text of which is set forth as Exhibit 99.1.

Item 8.01. Other Events.

On January 28, 2020, the Company announced that its Board of Directors had authorized an additional share repurchase program for up to $2 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws from time to time in the open market, through privately negotiated transactions, or otherwise.

On January 28, 2020, the Company also announced that its Board of Directors had declared a quarterly cash dividend of $0.43 per share of the Company’s common stock. The dividend will be paid on March 31, 2020 to stockholders of record at the close of business on March 2, 2020.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits:

Exhibit 99.1				Press Release, dated January 28, 2020.
Exhibit 104				Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 28, 2020